Literature DB >> 24986875

Age and aging in blood disorders: multiple myeloma.

Sonja Zweegman1, Antonio Palumbo2, Sara Bringhen2, Pieter Sonneveld3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24986875      PMCID： PMC4077073          DOI： 10.3324/haematol.2014.110296

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  28 in total

1.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

Review 2.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

3.  Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Authors:  Peter M Fayers; Antonio Palumbo; Cyrille Hulin; Anders Waage; Pierre Wijermans; Meral Beksaç; Sara Bringhen; Jean-Yves Mary; Peter Gimsing; Fabian Termorshuizen; Rauf Haznedar; Tommaso Caravita; Philippe Moreau; Ingemar Turesson; Pellegrino Musto; Lotfi Benboubker; Martijn Schaafsma; Pieter Sonneveld; Thierry Facon
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

4.  Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

Authors:  Maria-Victoria Mateos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Authors:  María-Victoria Mateos; Albert Oriol; Joaquín Martínez-López; Norma Gutiérrez; Ana-Isabel Teruel; Raquel de Paz; José García-Laraña; Enrique Bengoechea; Alejandro Martín; Joaquín Díaz Mediavilla; Luis Palomera; Felipe de Arriba; Yolanda González; Jose-Mariano Hernández; Ana Sureda; José-Luis Bello; Joan Bargay; Francisco-Javier Peñalver; José-María Ribera; María-Luisa Martín-Mateos; Ramón García-Sanz; María-Teresa Cibeira; María-Luisa Martín Ramos; María-Belén Vidriales; Bruno Paiva; María-Angeles Montalbán; Juan-José Lahuerta; Joan Bladé; Jesús-Fernando San Miguel
Journal:  Lancet Oncol       Date:  2010-08-23       Impact factor: 41.316

6.  Prognostic value of PINI index in patients with multiple myeloma.

Authors:  Sophie Dupire; Mathieu Wemeau; Houria Debarri; Laurent Pascal; Benedicte Hivert; Christophe Willekens; Eileen Boyle; Salomon Manier; Thielemans Béatrice; Brigitte Onraed; Jean-Luc Faucompré; Bernadette Hennache; Charles Dumontet; Thierry Facon; Xavier Leleu
Journal:  Eur J Haematol       Date:  2012-01-04       Impact factor: 2.997

Review 7.  Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Authors:  Antonio Palumbo; Sara Bringhen; Heinz Ludwig; Meletios A Dimopoulos; Joan Bladé; Maria V Mateos; Laura Rosiñol; Mario Boccadoro; Michele Cavo; Henk Lokhorst; Sonja Zweegman; Evangelos Terpos; Faith Davies; Christoph Driessen; Peter Gimsing; Martin Gramatzki; Roman Hàjek; Hans E Johnsen; Fernando Leal Da Costa; Orhan Sezer; Andrew Spencer; Meral Beksac; Gareth Morgan; Hermann Einsele; Jesus F San Miguel; Pieter Sonneveld
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

8.  A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences.

Authors:  Thérèse Nilsson; Mattias Höglund; Stig Lenhoff; Lars Rylander; Ingemar Turesson; Jan Westin; Felix Mitelman; Bertil Johansson
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

9.  Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.

Authors:  Michael Schaapveld; Otto Visser; Sabine Siesling; Cees G Schaar; Sonja Zweegman; Edo Vellenga
Journal:  Eur J Cancer       Date:  2010-01       Impact factor: 9.162

10.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528
View more
  16 in total

1.  Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis.

Authors:  C Minoia; G Pisapia; G Palazzo; C Ingrosso; M Buonanno; C Spinosa; A Prudenzano; G Pricolo; P Mazza
Journal:  Bone Marrow Transplant       Date:  2015-08-17       Impact factor: 5.483

2.  Aging and blood disorders: new perspectives, new challenges.

Authors:  Dominique Bron; Lionel Ades; Tamas Fulop; Valentin Goede; Reinhard Stauder
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

3.  Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.

Authors:  Monika Engelhardt; Sandra Maria Dold; Gabriele Ihorst; Alexander Zober; Mandy Möller; Heike Reinhardt; Stefanie Hieke; Martin Schumacher; Ralph Wäsch
Journal:  Haematologica       Date:  2016-06-16       Impact factor: 9.941

4.  Search for multiple myeloma risk factors using Mendelian randomization.

Authors:  Molly Went; Alex J Cornish; Philip J Law; Ben Kinnersley; Mark van Duin; Niels Weinhold; Asta Försti; Markus Hansson; Pieter Sonneveld; Hartmut Goldschmidt; Gareth J Morgan; Kari Hemminki; Björn Nilsson; Martin Kaiser; Richard S Houlston
Journal:  Blood Adv       Date:  2020-05-26

5.  The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study.

Authors:  B E Oortgiesen; E N van Roon; P Joosten; R E Kibbelaar; H Storm; S Hovenga; B van Rees; G Woolthuis; N Veeger; E G de Waal; M Hoogendoorn
Journal:  Eur J Clin Pharmacol       Date:  2017-03-03       Impact factor: 2.953

Review 6.  Tretatment approach of nontransplant patients with multiple myeloma.

Authors:  Svetlana B Krstevska; Tatjana Sotirova; Trajan Balkanov; Sonja Genadieva-Stavric
Journal:  Mater Sociomed       Date:  2014-10-29

7.  The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.

Authors:  Henrik Gregersen; Annette Juul Vangsted; Niels Abildgaard; Niels Frost Andersen; Robert Schou Pedersen; Ulf Christian Frølund; Carsten Helleberg; Bettina Broch; Per Trøllund Pedersen; Peter Gimsing; Tobias Wirenfeldt Klausen
Journal:  Cancer Med       Date:  2017-06-22       Impact factor: 4.452

8.  N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma.

Authors:  Paolo Milani; S Vincent Rajkumar; Giampaolo Merlini; Shaji Kumar; Morie A Gertz; Giovanni Palladini; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Nelson Leung; David Dingli; John A Lust; Yi Lin; Prashant Kapoor; Ronald S Go; Yi L Hwa; Wilson I Gonsalves; Steven R Zeldenrust; Robert A Kyle; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

9.  SRC3 expressed in BMSCs promotes growth and migration of multiple myeloma cells by regulating the expression of Cx43.

Authors:  Jie Jin; Tao Wang; Yu Wang; Shidi Chen; Zheng Li; Xiang Li; Jiazhen Zhang; Jin Wang
Journal:  Int J Oncol       Date:  2017-10-20       Impact factor: 5.650

10.  KLF10 inhibits cell growth by regulating PTTG1 in multiple myeloma under the regulation of microRNA-106b-5p.

Authors:  Mimi Zhou; Jinqiu Chen; Hui Zhang; Hailing Liu; Huan Yao; Xiaman Wang; Wanggang Zhang; Yingren Zhao; Nan Yang
Journal:  Int J Biol Sci       Date:  2020-05-15       Impact factor: 10.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.